Data from full set of subjects was statistically significant for the primary efficacy endpoint of daytime cough frequency reduction (p
Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
On 6ix: 6ix.com/news/trevi-therapeutics-announces-positive-data-from-full-set-of-subjects-in-phase-2-canal
Watch Trevi Therapeutics' latest callTrevi Therapeutics (NASDAQ:TRVI) Q2 2026 Earnings Call · Replay · Aug 6Read the transcript of Trevi Therapeutics (NASDAQ:TRVI) Q2 2026 Earnings CallTrevi Therapeutics, Inc. on 6ix
In the deck
Story so far
- Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis
- Trevi Therapeutics Hosting Key Opinion Leader Webinar on the Seriousness of Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
- Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough
Earlier from Trevi Therapeutics
- Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
- Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022
- Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release
- Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
- Trevi Therapeutics to Present at Upcoming August Conferences
Later from Trevi Therapeutics
- Trevi Therapeutics Announces Proposed Public Offering
- Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting
- Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022
- Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference
- Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
Follow Trevi Therapeutics into a list and get an email when it puts out news.
Follow Trevi Therapeutics